Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Conditions

Multiple Sclerosis 2Carcinoma in Situ 2Sarcoma, Kaposi 1Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis, Chronic Progressive 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

fludarabine 4Cyclophosphamide 4Specimen Handling 2Nivolumab 2Natalizumab 2Interferon beta-1b 2Fingolimod Hydrochloride 2Blood Specimen Collection 2teriflunomide 1nabiximols 1gadobutrol 1gadobenic acid 1cabozantinib 1Surveys and Questionnaires 1Respiratory Therapy 1Registries 1Platinum Compounds 1Platelet Transfusion 1Plasma Exchange 1Phlebotomy 1OM 89 1Mn-PyC3A 1Medical Marijuana 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Ipilimumab 1Interferon beta-1a 1Injections 1Gadolinium DTPA 1Fish Oils 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Sclerosis × Interferon beta-1b × Clear all
NCT02486640 2023-07-24

BETAPREDICT

Bayer

Completed
162 enrolled

Carcinoma in Situ, Multiple Sclerosis

NCT03134573 2019-03-26

PROmyBETAapp

Bayer

Completed
96 enrolled

Carcinoma in Situ, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡